Fibrosis regression in chronic liver disease: the pathologist's view
- Journal
- Journal of hepatology (Q1)
- Published
- 24 July 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Alastair D Burt, Cynthia Behling, Annette S H Gouw, Prodromos Hytiroglou, Carolin Lackner, Venancio A F Alves, et al.
- PMID
- 42497924
- DOI
- 10.1016/j.jhep.2026.07.018
Why clinicians should know about it
- Picked for Histology (top studies of the week, 26 July 2026).
Abstract
Numerous observations have indicated that significant amounts of liver fibrosis can either completely disappear or be substantially remodelled following removal of the initiating agent or with therapeutic intervention. Reversal of established cirrhosis has also been documented. Studies of fibrosis reversal utilize semiquantitative staging which was developed for progressive disease and which is limited by its categorical nature. A more nuanced system, the Beijing P-I-R classification is only validated in viral liver disease. The clinical significance of regressive features is hitherto unstudied. In this brief review, we are addressing shortcomings in (i) the histological assessment of fibrosis regression across the whole spectrum of common chronic liver diseases and (ii) identification of a point of no return in advanced fibrosis and argue that the hepatopathologists' community should rise to such challenges, perhaps hastened by development of artificial intelligence solutions applied to liver biopsies.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.